Literature DB >> 10755790

Uterine leiomyosarcoma--a Singapore experience.

L T Soh1, S H Chew, L Ang.   

Abstract

Uterine leiomyosarcoma is an aggressive tumour. In our retrospective series of 27 patients, there were 25 with nonmyxoid high-grade leiomyosarcoma of the uterus. The stage distribution was Stage 1, 16; Stage 3, 5 and Stage 4, 4. In the patients with Stage 1 disease, 3 of the 8 patients who received adjuvant chemotherapy subsequently developed recurrent disease. In contrast, 6 of the 8 patients who did not receive adjuvant chemotherapy subsequently developed recurrent disease; 2 of the patients in the latter group also received adjuvant radiotherapy. Six of the 9 women with recurrences were distant 'failures' alone, 2 were both distant and pelvic 'failures' and 1 was pelvic 'failure' alone. All the patients with advanced-stage disease eventually succumbed to the disease despite the therapies given. This study is small and retrospective but it suggests that there might be a role for adjuvant chemotherapy in the management of the early stage of this disease.

Entities:  

Mesh:

Year:  1999        PMID: 10755790     DOI: 10.1111/j.1479-828x.1999.tb03383.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  3 in total

1.  Leiomyosarcoma of the female breast.

Authors:  E Székely; L Madaras; J Kulka; B Járay; L Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 2.  Is Adnexectomy Mandatory at the Time of Hysterectomy for Uterine Sarcomas? A Systematic Review and Meta-Analysis.

Authors:  Carlo Ronsini; Aniello Foresta; Matteo Giudice; Antonella Reino; Marco La Verde; Luigi Della Corte; Giuseppe Bifulco; Pasquale de Franciscis; Stefano Cianci; Vito Andrea Capozzi
Journal:  Medicina (Kaunas)       Date:  2022-08-23       Impact factor: 2.948

Review 3.  Laparoscopic surgery on broken points for uterine sarcoma in the early stage decrease prognosis.

Authors:  Hong Liu; Yi Zhu; Guo-Nan Zhang; Chang Wang; Chao Li; Yu Shi
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.